Introduction

Allergic rhinitis (AR) is a type 1 immediate hypersensitivity reaction resulting from an immunoglobulin E (IgE) mediated immune response on exposure to an allergen. It is estimated that 20 million to 40 million US population suffer from this condition and studies conducted in various countries reported a prevalence of rhinitis of 3% to 19% (1). Its prevalence among the school children in Kelantan, Malaysia, was 27%. The prevalence is higher in 12 years old to 14 years old age group (38.2%) than that in the 5 years old to 7 years old age group (18.2%) (2). Another study of patients newly diagnosed with AR in Malaysia showed that 10% and 21.1% had mild and moderate-severe intermittent AR, respectively, and 20% and 48.9% of patients showed mild and moderate-severe persistent AR, respectively (3). This is a long-standing disease and may affect patients’ quality of life considerably.

AR has caused significant impairments in sleep, performance at work and school, as well as difficulties in social interactions. Quality of life is significantly affected, with sleeping difficulties being the most frequently reported problem, followed by symptoms of headaches, fatigue and malaise (4). These symptoms will directly impair the patients’ concentration and productivity in the workplace, therefore, interrupting their daily activity levels (5). In children, sleep disturbance showed that 10% and 21.1% had mild and moderate-severe intermittent AR, respectively, and 20% and 48.9% of patients showed mild and moderate-severe persistent AR, respectively (3). This is a long-standing disease and may affect patients’ quality of life considerably.

To cite this article: Ishak MN, Md Shukri N, Ramli RR. The effectiveness of budesonide nasal irrigation in patients with allergic rhinitis. Malays J Med Sci. 2022;29(1):34–42. https://doi.org/10.21315/mjms2022.29.1.4

To link to this article: https://doi.org/10.21315/mjms2022.29.1.4

Abstract

Background: Allergic rhinitis (AR) is a long-standing disease and has been shown to cause significant impairment in patients’ quality of life. Saline nasal irrigation is a proven adjunct in the treatment of AR. The addition of steroid to the saline solution can provide local steroid effect and increase the effectiveness of this technique. Our study aimed to determine the effectiveness of budesonide nasal irrigation as an adjunct to the treatment of AR, compared with saline nasal irrigation.

Methods: This was a randomised controlled study involving 99 patients diagnosed with AR, half of whom were treated with saline nasal irrigation and the other half with budesonide nasal irrigation. Parameters measured include the Sino-Nasal Outcome Test (SNOT-22) questionnaire, endoscopic nasal examination findings and blood eosinophil count.

Results: Patients treated with budesonide nasal irrigation had significant improvement in total SNOT-22 score \( (P < 0.001) \) and improvement in the endoscopic nasal examination findings, such as nasal mucosa oedema and secretions \( (P < 0.001) \). However, there was no significant improvement of blood eosinophil count in patients treated with either budesonide or saline nasal irrigation.

Conclusion: Budesonide nasal irrigation is effective as an adjunct in the treatment of AR.

Keywords: allergic rhinitis, nasal irrigation, budesonide, sino-nasal outcome test, endoscopy
and fatigue directly impact their learning abilities and have also been implicated in behavioural disturbances (6, 7).

Treatment of AR includes allergen avoidance, antihistamine medications and intranasal steroid sprays (intranasal corticosteroid [INS]). INS is the most effective single maintenance therapy for AR that causes few side effects at the recommended doses. INS is particularly effective in the treatment of nasal congestion. Examples of INS agents include beclomethasone, flunisolide, budesonide, fluticasone propionate, mometasone furoate, fluticasone furoate and ciclesonide. Comparative studies among different glucocorticoid nasal sprays have not demonstrated significant differences in efficacy (8, 9). INS is more effective than oral antihistamines for relief of nasal blockage, nasal discharge, sneezing, nasal itchiness and postnasal drip, as demonstrated in various randomised trials and a meta-analysis (10, 11). Most studies have also favoured INS over antihistamine sprays, owing to the local anti-inflammatory effect of the corticosteroid which significantly reduces the production and activity of proinflammatory mediators such as cytokines, adhesion molecules, eosinophils and mast cells (12, 13).

Nasal irrigation is a proven adjunct in the treatment of AR. A few types of solutions can be used for nasal irrigation in AR patients, including hypotonic, isotonic or hypertonic type saline, apart from steroid nasal irrigation (14). Few studies have demonstrated that hypertonic saline is better than normal saline, possibly because of the osmotic effect of hypertonicity which induces water transport through the mucosal epithelial membrane leading to a reduction in mucosal oedema (15, 16).

Saline nasal irrigation renders mechanical cleansing of contaminants, mucus, crust and cell debris. Apart from that, it also reduces the local concentrations of pro-inflammatory mediators, humidifies the nasal mucosa and enhances mucociliary clearance (17, 18). A study by Tano and Tano (19) showed that twice-daily nasal spraying with isotonic saline significantly reduced the number of days with nasal blockage and secretion. Hypertonic nasal irrigation has been demonstrated to be beneficial in improving the quality of life in patients with sinusitis (14, 20).

The addition of steroids in nasal irrigation solution can affect the production and activity of cytokines, adhesion molecules, mast cells, and eosinophils, thus reducing the inflammation and oedema of the nasal mucosa (21). With this combined effect of mechanical cleansing and efficient steroid delivery, the use of budesonide nasal irrigation is very promising as an adjunct in the treatment of AR.

However, there is no study which looked into the effectiveness of nasal steroid irrigation in AR patients. Nonetheless, few studies had observed the effect of nasal steroid irrigation after endoscopic sinus surgery in chronic rhinosinusitis patient. Snidvongs et al. (22) in 2012 revealed that chronic rhinosinusitis (CRS) patients undergoing endoscopic sinus surgery had significantly more improvement in symptoms and endoscopy scores after receiving steroid nasal irrigation. Another study by Jang et al. (23) also concluded that the addition of budesonide nasal irrigation is helpful in the postoperative management of patients with CRS.

The purpose of this study is to describe the effects of budesonide nasal irrigation in AR patients, by comparing the Sino-Nasal Outcome Test (SNOT-22) scores, nasal endoscopy findings (turbinate hypertrophy, mucosal oedema and secretion) and serum eosinophil levels between budesonide nasal irrigation and saline nasal irrigation groups of AR patients.

**Methods**

This randomised controlled study was conducted in Hospital Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia, from 1 November 2018 until 1 November 2019. Subjects were recruited from Otorhinolaryngology-Head and Neck Surgery (ORL-HNS) clinic in Hospital Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia. The subjects with AR have the cardinal symptoms of watery rhinorrhea, bilateral nasal obstruction, nasal itchiness and excessive sneezing. Allergic rhinitis and its impact on asthma (ARIA) guideline was used to categorise the subjects according to severity and persistence of the symptoms (24). Systematic random sampling method was used. Patients who were 18 years old and above, with moderate–severe intermittent, or mild and moderate–severe persistent AR were included in the study. Patients who had a prior history of nasal surgery, patients with nasal polyps or sinonasal tumour and pregnant patients were excluded from the study.
Using the Power and Sample Size (PS) software, the calculated sample size, including 20% dropout, was 118 patients with AR, of whom half used saline nasal irrigation and the other half used budesonide nasal irrigation. The selection of patients for each group was made using a smartphone random generator application by an appointed staff nurse without the knowledge of attending doctor. All patients continued using intranasal corticosteroid (INS) and antihistamines for this research duration. The treatment duration was three months from the initiation of the treatment till the next follow-up. During the first visit, all patients underwent SNOT-22 questionnaire review, endoscopic nasal examination and blood test for eosinophil count. For endoscopic nasal examination, the parameters assessed were the presence and severity of turbinate hypertrophy, mucosal oedema and secretions. For the blood eosinophil count, a 2 mL blood sample was taken in plain specimen bottle and sent to the pathology laboratory for processing by an assigned staff. The blood sample was analysed for full blood count and differential count, with eosinophil count. It was measured using Automated Haematology Analyser (XN-1000, S/N: 24485).

Patients were taught the proper technique of nasal irrigation using the nasal saline rinse kit (NeilMed® sinus rinse). An instructional video on how to use the sinus rinse was used to assist in educating patients in proper sinus irrigation. All subject use 250 mL squeeze bottles (Sinus Rinse, NeilMed® Pharmaceuticals Inc., United States) for nasal irrigation. Half of the patients used only saline solution while the other half added three puffs of budesonide inhaler (Budecort 200; Cipla Ltd., India) into the 250 mL of saline solution in the squeeze bottle. Each attenuation will deliver 200 mcg of budesonide, with a total amount of 0.6 mg per bottle. Half of the solution (125 mL) was used for each nasal cavity, irrigated once daily for 3 months. The usage of squeeze bottle was chosen as the delivery device due to studies that showed a better steroid contact with sinus mucosa while providing a small (2.5% ± 1.6%) residual fluid (25, 26).

The patients continued using the same treatment dosage for 3 months before the second assessment. After 3 months of treatment, all subjects were administered the same questionnaire, examination and investigations at the first visit. Treatment diary was used to help improve medication adherence in the patients. During follow-up visits, patients were also asked about any side effects that they experienced, such as nasal dryness, nasal itchiness or pain, epistaxis, breathing difficulty or blurring of vision. Other side effects included persistent cough, sore throat, nausea, vomiting and fever.

Data collected were entered and analysed using SPSS version 22. Descriptive statistics was used to summarise the sociodemographic characteristics of the subjects. Numerical data was presented as mean (standard deviation [SD]) or median based on their normality distribution. Categorical data was presented as frequency (%). The mean differences before and after the treatment for each group were measured using the t-test and the level of significance was set at 0.05. The effectiveness of budesonide nasal irrigation compared with saline nasal irrigation was displayed by measuring the difference of improvement for each group by using an independent t-test. The outcomes were presented in table form.

Results

Participants Characteristic

A total of 102 participants were recruited for this study. However, three patients defaulted the second visit and were excluded; therefore, only 99 patients remained in the study. The data obtained are expressed as mean (SD) for numerical and frequency (%) for categorical variables. The results show that the mean age of the total subjects is 39.17 and the standard deviation is 17.23. Female participants were 63.6%, while 36.4% are male. The majority are Malay (77.8%), while few are Chinese and Indian (11.1%). The intervention group (budesonide nasal irrigation) and control (saline nasal irrigation) group are evenly distributed.

AR patients treated with budesonide nasal irrigation showed significant improvement in all the symptoms listed in the SNOT-22 questionnaire, while patients treated with saline nasal irrigation showed significant improvement in only a few of the symptoms (Table 1). The highest percentage of improvement for SNOT-22 symptoms is seen in thick nasal discharge in patients treated with budesonide nasal irrigation (Figure 1). There was significant improvement (P < 0.001) in the total symptom score of patients treated with budesonide nasal irrigation compared with those treated with saline nasal irrigation (mean improvement: 13.93; 95% CI: 8.05, 19.81) (Table 2).
There was no significant improvement of inferior turbinate hypertrophy after treatment, in patients who used either budesonide nasal irrigation or saline nasal irrigation (Table 3). However, there was a significant improvement ($P < 0.001$) of nasal mucosal oedema in patients treated with budesonide nasal irrigation compared with those treated with saline nasal irrigation (mean improvement: 0.42; 95% CI: 0.25, 0.59). In terms of nasal secretions in patients treated with budesonide nasal irrigation and saline nasal irrigation, there was a significant improvement found ($P < 0.001$) in the budesonide nasal irrigation group (mean improvement: 0.72; 95% CI: 0.51, 0.92) (Table 4).

There was no significant improvement of blood eosinophil count in both the patient groups (Table 5).

### Table 1. Comparison of SNOT-22 score between AR patients treated with budesonide nasal irrigation and saline nasal irrigation

| Symptoms                      | Saline          | Budesonide        | $P$-value | $P$-value |
|-------------------------------|-----------------|-------------------|----------|----------|
|                               | Pre- *          | Post- *           |          |          |
| 1 Need to blow nose           | 2.52 (1.09)     | 1.73 (1.20)       | < 0.001  | 2.84 (1.05) | 1.53 (1.02) | < 0.001 |
| 2 Nasal blockage              | 2.76 (1.02)     | 2.24 (1.15)       | 0.007    | 3.18 (0.88) | 1.69 (0.95) | < 0.001 |
| 3 Sneezing                    | 2.82 (1.13)     | 2.02 (1.19)       | < 0.001  | 3.24 (0.93) | 1.90 (1.04) | < 0.001 |
| 4 Runny nose                  | 2.74 (1.10)     | 1.96 (1.36)       | < 0.001  | 3.12 (1.18) | 1.79 (0.988) | < 0.001 |
| 5 Cough                       | 1.41 (1.10)     | 1.37 (1.15)       | 0.785    | 1.56 (1.18) | 0.88 (1.01) | < 0.001 |
| 6 Post nasal discharge        | 2.16 (1.36)     | 1.55 (1.39)       | 0.002    | 2.63 (1.33) | 1.67 (1.14) | < 0.001 |
| 7 Thick nasal discharge       | 2.04 (1.23)     | 1.24 (1.09)       | < 0.001  | 2.47 (1.23) | 0.83 (0.96) | < 0.001 |
| 8 Ear fullness                | 1.16 (1.24)     | 1.02 (1.23)       | 0.398    | 2.10 (1.48) | 1.04 (1.19) | < 0.001 |
| 9 Dizziness                   | 1.44 (1.38)     | 1.16 (1.46)       | 0.113    | 1.82 (1.65) | 0.84 (1.03) | < 0.001 |
| 10 Ear pain                   | 0.82 (1.12)     | 0.78 (0.98)       | 0.792    | 1.39 (1.37) | 0.73 (0.995) | < 0.001 |
| 11 Facial pain                | 0.94 (1.27)     | 0.84 (1.18)       | 0.294    | 1.48 (1.52) | 0.65 (0.91) | < 0.001 |
| 12 Decrease smell/taste       | 1.22 (1.30)     | 0.78 (1.18)       | 0.029    | 1.64 (1.50) | 0.73 (0.98) | < 0.001 |
| 13 Difficulty falling asleep  | 1.40 (1.36)     | 1.06 (1.42)       | 0.055    | 1.71 (1.60) | 0.80 (1.15) | < 0.001 |
| 14 Wake up at night           | 1.36 (1.54)     | 1.04 (1.49)       | 0.058    | 1.55 (1.67) | 0.61 (1.04) | < 0.001 |
| 15 Lack of good night’s sleep | 1.32 (1.50)     | 1.04 (1.41)       | 0.142    | 1.65 (1.55) | 0.75 (1.08) | < 0.001 |
| 16 Wake up tired              | 1.46 (1.46)     | 1.16 (1.25)       | 0.037    | 1.88 (1.45) | 0.94 (1.09) | < 0.001 |
| 17 Fatigue                    | 1.28 (1.37)     | 1.18 (1.33)       | 0.392    | 1.76 (1.41) | 0.86 (0.94) | < 0.001 |
| 18 Reduced productivity       | 1.18 (1.30)     | 0.86 (1.23)       | 0.037    | 1.45 (1.39) | 0.65 (0.89) | < 0.001 |
| 19 Reduced concentration      | 1.14 (1.41)     | 1.08 (1.37)       | 0.726    | 1.73 (1.40) | 0.75 (0.93) | < 0.001 |
| 20 Frustrated                 | 1.02 (1.44)     | 1.00 (1.37)       | 0.811    | 1.55 (1.44) | 0.71 (1.08) | < 0.001 |
| 21 Sad                        | 0.60 (1.13)     | 0.53 (1.12)       | 0.441    | 0.98 (1.22) | 0.33 (0.69) | < 0.001 |
| 22 Embarrassed                | 0.62 (1.14)     | 0.53 (1.12)       | 0.417    | 0.90 (1.16) | 0.38 (0.76) | < 0.001 |

Note: * mean (standard deviation)
Figure 1. Percentage of improvement of SNOT-22 symptoms between AR patients treated with budesonide nasal irrigation and saline nasal irrigation

Table 2. Mean difference of improvement of total SNOT-22 score between AR patients treated with budesonide nasal irrigation and saline nasal irrigation

|                              | Saline mean (SD) | Budesonide mean (SD) | Mean difference (95% CI) | t-statistics (df) | P-value |
|------------------------------|------------------|-----------------------|--------------------------|-------------------|---------|
| Improvement of total SNOT-22 score | -7.56 (14.78)    | -21.49 (14.70)        | 13.93 (8.05, 19.81)      | 4.70 (97.00)      | < 0.001 |

Table 3. Comparison of endoscopic nasal examination findings between AR patients treated with budesonide nasal irrigation and saline nasal irrigation

| Endoscopic finding | Pre- a | Post- a | Mean differences * | P-value |
|--------------------|--------|---------|--------------------|---------|
| IT hypertrophy     | Saline | 2.00 (0.00) | 2.00 (0.00) | - |
|                    | Budesonide | 2.00 (0.00) | 2.00 (0.00) | - |
| Oedema             | Saline | 3.24 (0.95) | 3.04 (1.02) | 0.20 (-0.02, 0.42) | 0.067 |
|                    | Budesonide | 3.47 (0.87) | 2.41 (0.84) | 1.06 (0.78, 1.34) | < 0.001 |
| Secretion          | Saline | 2.04 (0.91) | 1.76 (1.03) | 0.29 (-0.03, 0.60) | 0.075 |
|                    | Budesonide | 2.20 (0.91) | 0.49 (0.87) | 1.71 (1.43, 1.995) | < 0.001 |

Notes: a mean (standard deviation); IT: inferior turbinate
effectiveness of budesonide nasal irrigation in AR patients.

This randomised controlled study looks at the effectiveness of budesonide nasal irrigation in AR patients. This was measured by comparing saline nasal irrigation with or without steroid, using three main indicators, which were symptoms (SNOT-22), clinical evaluation (via endoscopic nasal examination) and blood eosinophil levels.

SNOT-22 questionnaire reviewed the symptoms associated with AR which revealed that AR patients treated with budesonide nasal irrigation had significant improvement in all the symptoms listed in the SNOT-22 questionnaire. Whereas, patients treated with saline nasal irrigation showed significant improvement in only a few of the symptoms, namely the need to blow nose, sneezing, runny nose and thick nasal discharge.

This may be due to the effect of mechanical cleansing of saline solution. From our questionnaires, the most common symptoms are nasal blockage, sneezing, runny nose, need to blow nose and postnasal discharge. Thick nasal discharge has the highest percentage of improvement after treatment with both modalities, which was significantly better with budesonide nasal irrigation. This correlated with the clinical endoscopy findings which showed that the nasal secretions in patients treated with budesonide nasal irrigation reduced significantly.

Endoscopic nasal examination parameters assessed include inferior turbinate hypertrophy, nasal mucosal edema and nasal secrections. There was significant improvement of nasal mucosal oedema and nasal secretions in patients treated with budesonide nasal irrigation compared with those in patients using saline nasal irrigation. The reduction of nasal secretion may be due to the effect of mechanical cleansing of contaminants, mucus, crust and cell debris, which reduces the local concentrations of pro-inflammatory mediators and therefore enhances the mucociliary clearance (17, 18). The presence of steroids in the irrigation solution significantly affects the production and action of cytokines, mast cells and eosinophil. However, there was no significant improvement in inferior turbinate hypertrophy in patients using either budesonide or saline nasal irrigation.

The blood eosinophil count did not show a significant improvement after treatment in both groups. This finding may indicate that nasal irrigation, with either budesonide or saline, only exert local effects with minimal systemic effects, i.e. the blood eosinophil level. This finding also corresponds to studies which showed that the overall steroid exposure via nasal steroid irrigation is less than 5% of the total drug (24, 25). A local count of eosinophils in nasal mucosal scrapings may exhibit more valid biochemical parameters which correlate with AR (27) but due to the non-availability of these services at our centre, we used blood eosinophil levels.

**Conclusion**

Budesonide nasal irrigation is effective as an adjunct in the treatment for AR. Assessment of nasal symptoms and endoscopic nasal examination revealed significant improvement after three months of treatment with this method.
while continuing the main treatment, which is INS. We propose that this improvement may be due to the mechanical cleansing effect which also improved the efficiency of steroid delivery to the nasal mucosa.

Acknowledgements

We would like to show our gratitude to the Division of Research and Innovation, Universiti Sains Malaysia for without their support through the research grant, this study would not have been possible.

We thank our colleagues from the Department of ORL-HNS, School of Medical Sciences, Universiti Sains Malaysia who provided insight and expertise that greatly assisted the research. Apart from that, the assistance provided by the staff of ORL-HNS clinic, Universiti Sains Malaysia was greatly appreciated.

We would like to recognise the invaluable assistance of Madam Wan Nor Aziemah Wan Zainuddin, Madam Roazlina Ramli and all the staff of Haematology Laboratory, Universiti Sains Malaysia for carrying out the blood investigation needed in this study. We would also like to extend our gratitude to Ms Anusha from Jetpharma Sdn. Bhd. Malaysia for providing instruments used in this study.

Finally, we dedicate this research to our family who has been very supportive throughout every step of the research journey.

Ethics of Study

This study was approved by the Human Research Ethics Committee USM (USM/JEPEM/18080387) and was conducted according to the Helsinki Declaration with written consent obtained from each subject.

Conflict of Interest

None.

Funds

Bridging Grant from Research Creativity and Management Office (RCMO), Division of Research and Innovation, Universiti Sains Malaysia [304.PPSP.6316149].

Authors’ Contributions

Conception and design: RRR, NMS, MNI Analysis and interpretation of the data: RRR, NMS, MNI Drafting of the article: RRR, NMS, MNI Critical revision of the article for important intellectual content: RRR, NMS Final approval of the article: RRR, NMS Provision of study materials or patients: MNI Obtaining of funding: RRR Administrative, technical and logistic support: RRR, NMS Collection and assembly of data: MNI

Correspondence

Associate Professor Dr Ramiza Ramza Ramli MMed ORL-HNS (USM), Clinical Fellowship in Rhinology and Skull Base Surgery Department of Otorhinolaryngology-Head and Neck Surgery, School of Medical Sciences, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia. Tel: +609 767 3000 Fax: +609 767 3370 E-mail: ramizaramza@usm.my

References

1. Skoner DP. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol. 2001;108(1):S2–S8. https://doi.org/10.1067/mai.2001.115569
2. Quah BS, Razif A, Razak A, Hashim M, Hassan M. Prevalence of asthma, rhinitis and eczema among school children in Kelantan, Malaysia. Acta Paediatr Jpn. 1997;39(3):329–335. https://doi.org/10.1111/j.1442-200X.1997.tb03746.x
3. Asha’ari ZA, Yusof S, Ismail R, Che Hussin CM. Clinical features of allergic rhinitis and skin prick test analysis based on the ARIA classification: a preliminary study in Malaysia. Ann Acad Med Singap. 2010;39(8):619–624.
4. Meltzer EO, Nathan R, Derebery J, Stang PE, Campbell UB, Yeh WS, et al. Sleep, quality of life, and productivity impact of nasal symptoms in the United States: findings from the burden of rhinitis in America survey. *Allergy Asthma Proc.* 2009;30(3):244–254. https://doi.org/10.2500/aap.2009.30.3230

5. Bousquet J, Neukirch F, Bousquet PJ, Gehano P, Klossek JM, Le Gal M, et al. Severity and impairment of allergic rhinitis in patients consulting in primary care. *J Allergy Clin Immunol.* 2006;117(1):158–162. https://doi.org/10.1016/j.jaci.2005.09.047

6. Izquierdo-Dominguez A, Valero AL, Mullol J. Comparative analysis of allergic rhinitis in children and adults. *Curr Allergy Asthma Rep.* 2013;13(2):142–151. https://doi.org/10.1007/s11882-012-0331-y

7. Meltzer EO, Blaiss MS, Derebery MJ, Mahr TA, Gordon BR, Sheth KK, et al. Burden of allergic rhinitis: results from the pediatric allergies in America survey. *J Allergy Clin Immunol.* 2009;124(3 Suppl 1):S43–S70. https://doi.org/10.1016/j.jaci.2009.05.013

8. Berger W. Triamcinolone acetonide aqueous nasal spray and fluticasone propionate are equally effective for relief of nasal symptoms in patients with seasonal allergic rhinitis. *Otolaryngol Head Neck Surg.* 2003;129(1):16–23. https://doi.org/10.1016/s0194-5998(03)00526-6

9. Mandl M, Nolop K, Lutsky B, Group Pit-S. Comparison of once daily mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis. *Ann Allergy Asthma Immunol.* 1997;79(4):370–378. https://doi.org/10.1016/s1081-1206(10)63030-x

10. Kaszuba SM, Baroody FM, Haney L, Blair C, Naclerio RM. Superiority of an intranasal corticosteroid compared with an oral antihistamine in the as-needed treatment of seasonal allergic rhinitis. *Arch Intern Med.* 2001;161(21):2581–2587. https://doi.org/10.1001/archinte.161.21.2581

11. Pullerits T, Praks L, Ristioja V, Löttvall J. Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis. *J Allergy Clin Immunol.* 2002;109(6):949–955. https://doi.org/10.1067/mai.2002.124467

12. Berlin JM, Golden SJ, Teets S, Lehman EB, Lucas T, Craig T. Efficacy of a steroid nasal spray compared with an antihistamine nasal spray in the treatment of perennial allergic rhinitis. *J Am Osteopath Assoc.* 2000;100(7 Suppl):8S–13S.

13. Carr W, Bernstein J, Lieberman P, Meltzer E, Bachert C, Price D, et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. *J Allergy Clin Immunol.* 2012;129(5):1282–1289. https://doi.org/10.1016/j.jaci.2012.01.077

14. Rabago D, Zgierska A, Mundt M, Barrett B, Bobula J, Maberry R. Efficacy of daily hypertonic saline nasal irrigation among patients with sinusitis: a randomised controlled trial. *J Fam Pract.* 2002;51(12):1049–1056.

15. Shoseyov D, Bibi H, Shai P, Shoseyov N, Shazberg G, Hurvitz H. Treatment with hypertonic saline versus normal saline nasal wash of pediatric chronic sinusitis. *J Allergy Clin Immunol.* 1998;101(5):602–605. https://doi.org/10.1016/s0091-6749(98)70166-6

16. Luk CK, Dulfano MJ. Effect of pH, viscosity and ionic-strength changes on ciliary beating frequency of human bronchial explants. *Clin Sci (Lond).* 1983;64(4):449–451. https://doi.org/10.1042/css0640449

17. Hermelingmeier KE, Weber RK, Hellmich M, Heubach CP, Mosges R. Nasal irrigation as an adjunctive treatment in allergic rhinitis: a systematic review and meta-analysis. *Am J Rhinol Allergy.* 2012;26(5):e119–e125. https://doi.org/10.2500/ajra.2012.26.3787

18. Satdhabudha A, Poachanukoon O. Efficacy of buffered hypertonic saline nasal irrigation in children with symptomatic allergic rhinitis: a randomised double-blind study. *Int J Pediatr Otorhinolaryngol.* 2012;76(4):583–588. https://doi.org/10.1016/j.ijporl.2012.01.022
19. Tano L, Tano K. A daily nasal spray with saline prevents symptoms of rhinitis. Acta Otolaryngol. 2009;124(9):1059–1062. https://doi.org/10.1080/00016480410017657

20. Heatley DG, McConnell KE, Kille TL, Leeverson GE. Nasal irrigation for the alleviation of sinonasal symptoms. Otolaryngol Head Neck Surg. 2001;125(1):44–48. https://doi.org/10.1067/mhn.2001.115909

21. Mygind N, Nielsen LP, Hoffmann H-J, Shukla A, Blumberga G, Dahl R, et al. Mode of action of intranasal corticosteroids. J Allergy Clin Immunol. 2001;108(1):S16–S25. https://doi.org/10.1067/mai.2001.115561

22. Snidvongs K, Pratt E, Chin D, Sacks R, Earls P, Harvey RJ. Corticosteroid nasal irrigations after endoscopic sinus surgery in the management of chronic rhinosinusitis. Int Forum Allergy Rhinol. 2012;2(5):415–421. https://doi.org/10.1002/alr.21047

23. Jang DW, Lachanas VA, Segel J, Kountakis SE. Budesonide nasal irrigations in the postoperative management of chronic rhinosinusitis. Int Forum Allergy Rhinol. 2013;3(9):708–711. https://doi.org/10.1002/alr.21189

24. Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010;126(3):466–476. https://doi.org/10.1016/j.jaci.2010.06.047

25. Kang TW, Chung JH, Cho SH, Lee SH, Kim KR, Jeong JH. The effectiveness of budesonide nasal irrigation after endoscopic sinus surgery in chronic rhinosinusitis with asthma. Clin Exp Otorhinolaryngol. 2017;10(1):91–96. https://doi.org/10.21053/ceo.2016.00220

26. DelGaudio JM, Wise SK. Topical steroid drops for the treatment of sinus ostia stenosis in the postoperative period. Am J Rhinol. 2018;20(6):563–567. https://doi.org/10.2500/ajr.2006.20.2904

27. Pal I, Babu AS, Halder I, Kumar S. Nasal smear eosinophils and allergic rhinitis. Ear Nose Throat J. 2017;96(10–11):E17–E22. https://doi.org/10.1177/0145561317096010-1105